Jushi Holdings Inc. Reports Unaudited, Preliminary Fourth Quarter and Full Year 2022 Financial Results
Q4 2022 Revenue Increased 16.6% YoY to $76.8 million and FY 2022 Revenue Increased 35.8% to a Record $284.3 million...
Day: March 31, 2023
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus
– IND application cleared within 6 months of in-licensing CABA-201 binder – – CABA-201 data package and experience from prior...
InvestmentPitch Media Video Discusses Reliq Health and its Signing of 10 Contracts Potentially Adding 5,000 new Patients to its iUGO Platform by Year End
VANCOUVER, British Columbia, March 31, 2023 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft...
Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders
Company Announcement, Helsinki, 31 March 2023 at 1 PM (EEST) Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders...
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Mendus AB: Change in number of shares and votes in Mendus AB (publ)
During March, the number of shares and votes in Mendus AB (publ) has changed as a result of 1,137,790 new...
Study shows significant improvement in bladder emptying with Coloplast’s Luja™ compared to competitor catheter
Luja Coloplast's intermittent male catheter LujaStudy results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete...
Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F
Saint-Herblain (France), March 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the...
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Pixium Vision to receive interactive communication...
BioSenic provides Financial Update and Financial Calendar 2023
INSIDE INFORMATION Mont-Saint-Guibert, Belgium, March 31, 2023, 7am CET - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company...
Jamieson Wellness Inc. Announces Filing of Management Information Circular for Annual and Special Meeting of Shareholders
TORONTO, March 30, 2023 (GLOBE NEWSWIRE) -- Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) announced today that...
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell...
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with...
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical...
Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update
Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to BMS collaboration,...
Lowell Farms Inc. Announces Audited Fourth Quarter and Fiscal Year 2022 Financial and Operational Results
SALINAS, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born vertically...
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in...